ArticleAdvanced biomedical research2023
Evaluation of the Effect of Aripiprazole Supplementation in the Prevention of Delirium in Patients Admitted to the General Intensive Care Unit.
Article in Advanced biomedical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To prove the position of aripiprazole as a preventive and safe agent in delirium in patients admitted to the intensive care unit (ICU), it is necessary to conduct randomized controlled clinical trials with appropriate design. Materials and Methods: In this study, 80 patients were randomly divided into two groups of 40. Group A received placebo mart for one week, and group B received 15 mg aripiprazole daily (dissolved in 10 cc) daily. As a criterion for assessing delirium, the Confusion Assessment methods for the ICU (CAM-ICUs) were evaluated daily for patients. At the end of the study, the trends of CAM-ICU and CAM-ICU changes on day 7 were compared between the two groups. All statistical tests were performed in two domains with a significance level of 5% using the Results: The use of aripiprazole in the studied indices was not statistically significant ( Conclusion: The use of aripiprazole with the approach of reducing the risk or controlling the occurrence of delirium on patients admitted to the intensive care unit, despite creating some beneficial effects such as reducing the length of hospital stay in the ICU, cannot be clearly and significantly effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.